Clinical trials
Esophageal Neoplasms trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
77 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 8 |
| 2023 | 7 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Unknown status | 21 |
| Recruiting | 12 |
| Active, not recruiting | 11 |
| Terminated | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 22 |
| Merck Sharp & Dohme LLC | 6 |
| Chang Gung Memorial Hospital | 5 |
| Novartis Pharmaceuticals | 3 |
| Taipei Veterans General Hospital, Taiwan | 3 |
| AstraZeneca | 2 |
| E-DA Hospital | 2 |
| Hoffmann-La Roche | 2 |
| Mackay Memorial Hospital | 2 |
| AbbVie | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Esophageal Neoplasms | 77 |
| Stomach Neoplasms | 19 |
| Carcinoma, Non-Small-Cell Lung | 11 |
| Squamous Cell Carcinoma of Head and Neck | 10 |
| Ovarian Neoplasms | 9 |
| Esophageal Squamous Cell Carcinoma | 8 |
| Neoplasm Metastasis | 7 |
| Uterine Cervical Neoplasms | 7 |
| Carcinoma, Renal Cell | 6 |
| Lung Neoplasms | 6 |
Trials
Showing 51 to 75 of 77. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.